Cardiovascular Disease Risk and Nonalcoholic Fatty Liver Disease
This Learning Center is a freely accessible educational platform for healthcare providers who may be involved in the identification and management of patients with NASH. Our goal is to ensure that you – the practicing clinician – have access to the most accurate, up-to-date information for the treatment of patients with NASH.
We encourage you to share this educational resource with your colleagues and your healthcare team.
Courses
Cardiovascular Disease Risk and Nonalcoholic Fatty Liver Disease
Credit Available: 0.5 AMA PRA Category 1 Credit(s)™; 0.5 ANCC contact hours
This activity will review the epidemiological link between NAFLD/NASH and CVD and the prevalence of CV death among NAFLD/NASH pts, identify pathological mechanisms linking NAFLD/ NASH and CVD and evaluate current and emerging risk reduction and management strategies to address CVD as part of overall NAFLD/NASH.
[Accreditation has expired. For informational purposes only.]
Course Faculty
Emerging Targeted Strategies to Mitigate Disease Progression in NAFLD/NASH
Credit Available: 0.75 AMA PRA Category 1 Credit(s)™; 0.75 ANCC contact hours
This activity will describe the biological targets and mechanisms of action of emerging therapies that address the underlying pathology of NAFLD/NASH and evaluate emerging NAFLD/NASH therapies, including combination therapy, considering their potential ability to mitigate progression to severe outcomes.
[Accreditation has expired. For informational purposes only.]
Course Faculty
Zobair Younassi, MD, MPH,FACP, FACG, AGAF, FAASLD (Course Director)